Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Campillo-Gimenez

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2025
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY DataHéloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, et al.
Urologic Oncology|June 17, 2017
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatmentSolène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2016
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular CarcinomaJulien Edeline, Jean-Frédéric Blanc, Philip Johnson, et al.
International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 11, 2024
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 TrialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 5, 2024
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trialLionel Perrier, Frédéric Balusson, Magali Morelle, et al.
JAMA Dermatology|July 16, 2020
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic MelanomaAngélique Brunot, Jean-Jacques Grob, Geraldine Jeudy, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2020
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
BMC Medical Informatics and Decision Making|October 3, 2021
A framework for validating AI in precision medicine: considerations from the European ITFoC consortiumRosy Tsopra, Xose Fernandez, Claudio Luchinat, et al.
International Journal of Cancer|July 19, 2019
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patientsEric Voog, Boris Campillo-Gimenez, Claude Elkouri, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2025
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY DataHéloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, et al.
Urologic Oncology|June 17, 2017
Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatmentSolène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2016
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular CarcinomaJulien Edeline, Jean-Frédéric Blanc, Philip Johnson, et al.
International Journal of Clinical Oncology|March 28, 2020
Implementation of a molecular tumor board at a regional level to improve access to targeted therapyHéloïse Bourien, Alexandra Lespagnol, Boris Campillo-Gimenez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 11, 2024
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 TrialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 5, 2024
Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trialLionel Perrier, Frédéric Balusson, Magali Morelle, et al.
JAMA Dermatology|July 16, 2020
Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic MelanomaAngélique Brunot, Jean-Jacques Grob, Geraldine Jeudy, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2020
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
BMC Medical Informatics and Decision Making|October 3, 2021
A framework for validating AI in precision medicine: considerations from the European ITFoC consortiumRosy Tsopra, Xose Fernandez, Claudio Luchinat, et al.
International Journal of Cancer|July 19, 2019
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patientsEric Voog, Boris Campillo-Gimenez, Claude Elkouri, et al.
Pageof 5